September 25, 2016 11:05 PM ET

Pharmaceuticals

Company Overview of Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Company Overview

Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research, development, production, and sale of biological products. Its products include Su peptide Health, an injection of mouse nerve growth factor; and Shu Taiqing, Gliclazide, Nabumetone, and aspirin. The company offers its products in the form of tablets, powders, capsules, and injections. Staidson (Beijing) Biopharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.

Beijing Economic and Technological Development Zone

Sea Road No. 36

Beijing,  100176

China

Founded in 2002

721 Employees

Phone:

86 10 6751 9888

Fax:

86 10 6751 9794

Key Executives for Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Staidson (Beijing) Biopharmaceuticals Co., Ltd. does not have any Key Executives recorded.

Staidson (Beijing) Biopharmaceuticals Co., Ltd. Key Developments

Staidson (Beijing) Biopharmaceuticals Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 19, 2016

Staidson (Beijing) Biopharmaceuticals Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 19, 2016, at 10:00 China Standard Time. Agenda: To consider 2016 the restricted stock incentive plan(draft) and its summary; to consider 2016 implementation and appraisal management measures for restricted stock incentive plan; and to consider mandate to the board to handle matters in relation to the stock option incentive plan.

Staidson (Beijing) Biopharmaceuticals Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 08, 2016

Staidson (Beijing) Biopharmaceuticals Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 08, 2016, at 10:00 China Standard Time. Agenda: To consider the repurchase and cancellation of locked restricted shares granted to the plan participants; to consider the change of the company's registered capital; and to consider the amendments to the company's articles of association.

Staidson Proposes Amendments to the Articles of Association

Staidson at its Extraordinary General Meeting to be held on September 8, 2016, will approve the amendments to the articles of association of the company.

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 18, 2016
InflaRx GmbH
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Staidson (Beijing) Biopharmaceuticals Co., Ltd., please visit www.staidson.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.